The loss of the retinoblastoma tumor suppressor gene (RB) is common in many human cancers, including prostate. We previously reported that engineered deletion of RB in prostate epithelial cells results in sustained cell growth in serum-free media, a predisposition to develop hyperplasia and dysplasia in prostate tissue recombinant grafts, and sensitization to hormonal carcinogenesis. Examining the molecular consequence of RB loss in this system, we show that cyclooxygenase-2 (COX-2) is significantly up-regulated following RB deletion in prostate tissue recombinants. To study the effect of RB deletion on COX-2 regulation, we generated wild-type (PrE) and RbÀ/À À/À (RbÀ/À À/ÀPrE) prostate epithelial cell lines rescued by tissue recombination. We show elevated COX-2 mRNA and protein expression in RbÀ/À À/ÀPrE cell lines with increased prostaglandin synthesis. We also find that loss of Rb leads to deregulated E2F activity, with increased expression of E2F target genes, and that exogenous expression of E2F1 results in elevated COX-2 mRNA and protein levels. COX-2 promoter studies reveal that E2F1 transcriptionally activates COX-2, which is dependent on the transactivation and DNA-binding domains of E2F1. Further analysis revealed that the E2F1 target gene, c-myb, is elevated in RbÀ/À À/ÀPrE cells and E2F1-overexpressing cells, whereas ectopic overexpression of c-myb activates the COX-2 promoter in prostate epithelial cells. Additionally, cotransfection with E2F1 and a dominantnegative c-myb inhibited E2F1 activation of the COX-2 promoter. Taken together, these results suggest activation of a transcriptional cascade by which E2F1 regulates COX-2 expression through the c-myb oncogene. This study reports a novel finding describing that deregulation of the Rb/E2F complex results in increased COX-2 expression and activity. (Cancer Res 2005; 65(9): 3633-42) 
Introduction
Cyclooxygenase (COX) or prostaglandin endoperoxide synthase is the rate-limiting enzyme that catalyzes the formation of prostaglandins from arachidonic acid. Two COX enzymes have been identified with similar enzymatic features; however, significant differences exist between them (reviewed in refs. 1, 2). COX-1 has been shown to be constitutively expressed in a majority of cells and performs housekeeping functions requiring immediate prostaglandin synthesis for vascular homeostasis, water resorption, and platelet aggregation. COX-2 has been described as an immediate early response gene and expressed predominantly in low levels.
COX-2 has shown to be proinflammatory and can be activated by mitogens, tumor promoters, cytokines, and stress-inducing agents (1, 2) .
There is accumulating evidence suggesting that COX-2 plays a role in human cancer. Elevated COX-2 expression has been observed in human colon cancer (3), lung cancer (4), cervical cancer (5) , and breast cancer (6) . Studies in animal models have shown that overexpression of COX-2 induced tumorigenesis and promoted cancer progression (7) . In contrast, inhibition of COX-2 decreased tumor incidence and progression (8, 9) . Although there is strong evidence implicating COX-2 in the development of certain human cancers, the role of COX-2 in prostate cancer remains unclear. In some studies, increased COX-2 expression has been detected in human prostate cancer tissues with a positive correlation between increased COX-2 with advancing prostate tumor stage (10) (11) (12) . In contrast, other studies showed positive COX-2 staining in normal tissues with loss of expression in prostate cancer (13, 14) . Other studies show that COX-2 is involved in early stages of prostate cancer with elevated COX-2 levels in benign proliferative hyperplastic lesions, high-grade prostatic intraepithelial neoplasia (HGPIN), and areas of the prostate with postinflammatory hyperproliferation, a condition thought to be a precursor to prostate cancer (13, 15) . To help define a role of COX-2 in prostate cancer, COX-2 has been examined in transgenic mouse models of prostate cancer TRAMP (16) and LPB-Tag (17) , which utilize the viral oncogene SV40 large T antigen to disrupt Rb and p53 tumor suppressor pathways to promote tumorigenesis. In both studies, COX-2 expression was elevated in HGPIN and early prostatic lesions, but was absent in late-stage tumors and sites of metastasis. These results support the role of COX-2 in the early development of prostate cancer and also suggest that disruption of the p53 and Rb pathways may be involved in COX-2 regulation. Because of the contrasting observations of COX-2 in prostate cancer, one endorsing elevated COX-2 and the other showing COX-2-independent mechanisms for prostate cancer progression, additional studies are required to examine the function and regulation of COX-2 in diverse populations of prostate epithelial and cancer cells.
Disruption of the Rb/E2F1 pathway may be a key event in the development of human cancers. The loss of the RB tumor suppressor gene has been reported in many human tumors including prostate (18) , breast (19) , colon (20) , and bladder (21) . The RB tumor suppressor gene encodes a 110 kDa phosphoprotein (Rb) that regulates the transition between G 1 and S phases of the cell cycle (reviewed in ref. 22) . Hypophosphorylated Rb binds to and sequesters the transcription factor E2F, thereby inhibiting transactivation of E2F target genes and ultimately inducing G 1 cell cycle arrest. Inactivation of Rb results in increased E2F activity, enhanced transcriptional activation of E2F target genes, and forward progression of the cell cycle (23) . Elevated E2F1 activity can induce hyperproliferation, hyperplasia, and p53-dependent apoptosis in E2F1 transgenic mice and transgenic mice that overexpress E2F1 under the keratin 5 promoter develop spontaneous tumors in keratin 5-expressing tissues (24, 25) . E2F1 can also cooperate with Ras to induce transformation of rat embryonic fibroblasts, induce tumors in mice, and can increase the invasive potential of cancer cells (26, 27) . Elevated expression of E2F1 has been observed in human breast cancers (28) , non-small cell lung cancer (29) , and salivary gland tumors (30) . The oncogenic capacity of E2F is thought to be related to its regulatory role in the expression of genes involved in cell cycle and cell proliferation; however, mRNA profiling of E2F1-overexpressing cells indicates that E2F1 regulates hundreds of genes, not only those involved in cell cycle but also oncogenes, genes involved in apoptosis, signal transduction, and transcriptional regulation, suggesting that E2F1 may have multiple roles in tumorigenesis (31) . Therefore, activation of E2F1 by disruption of the Rb tumor suppressor pathway may play a role in the development of cancer independent of cell cycle disruption.
Homozygous deletion of RB is lethal in embryonic mice, making it difficult to study the effects of RB loss in epithelial cells. To solve this problem, we developed a prostate tissue recombination model with homozygous deletion of RB, where RBÀ/À prostatic tissues are combined with rat urogenital mesenchyme (UGM) to generate UGM+RbÀ/À prostate tissues and cell lines (32, 33) . As a consequence of RB deletion, RBÀ/À cells are able to proliferate in serum-free conditions, have increased development of hyperplasia, and are susceptible to hormonal carcinogenesis (32, 33) . In the current study, we describe one of the consequences of RB loss in prostate epithelial cells, up-regulation of COX-2. We utilized wild-type (PrE) and RBÀ/À (RbÀ/ÀPrE) prostate epithelial cells lines rescued by tissue recombination to study the effect of RB inactivation on COX-2. Elevated COX-2 levels were present in RbÀ/ÀPrE cell lines and UGM+RbÀ/À recombinant tissue grafts in vivo. The increase in COX-2 expression correlated with elevated levels of prostaglandins and increased sensitivity to the COX-2 inhibitor NS-398. To further understand the mechanism(s) by which homozygous deletion of RB resulted in increased COX-2, we assessed whether the transcription factor, E2F1, plays a role in regulating COX-2. We show that RbÀ/ÀPrE cells have increased E2F activity and exogenous expression of E2F1 transcriptionally regulates COX-2. Furthermore, we show that E2F1 activation of COX-2 is dependent on the c-myb oncogene. This is the first study to describe a role of Rb/E2F1 in regulating COX-2 expression.
Materials and Methods
Tissue culture reagents and chemicals. The generation of PrE and RbÀ/ÀPrE cell lines was previously described (32) . Cells were maintained in RPMI 1640 culture medium supplemented with 5% fetal bovine serum (FBS), 100 units/mL penicillin, 100 Ag/mL streptomycin, and 2 mmol/L Lglutamine (Life Technologies, Inc., Gaithersburg, MD) and kept at 37jC in a humidified atmosphere of 5% CO 2 . The COX-2 inhibitor NS-398 and COX-1 inhibitor valeroyl salicylate acid (VSA) were purchased from Cayman Chemical, Co. (Ann Arbor, MI). For treatment with NS-398 or VSA, 5 Â 10 5 cells were plated in 100 mm 2 dishes for 24 hours. NS-398 or VSA was added to cells at the indicated concentrations and incubated for 4 days. Cell viability was monitored by trypan blue exclusion assay (Life Technologies).
Immunohistochemistry. The generation of UGM+Rb+/+ and UGM+RbÀ/À tissues have been previously described (33) . Tissue sections from UGM+Rb+/+ and UGM+RbÀ/À were deparaffinized in xylene and rehydrated in graduated alcoholic solutions and PBS. Endogenous peroxidase activity was blocked with 0.5% hydrogen peroxide in methanol for 5 minutes and washed in PBS before staining. Immunocytochemical staining for COX-2 (Cayman Chemical) was done at a 1:200 dilution at room temperature overnight. Goat anti-rabbit secondary antibody was applied for 1 hour at room temperature. Antigen retrieval was accomplished with a sodium citrate solution for 10 minutes in a microwave.
Reverse transcription-PCR. RNA was prepared from cells using Qiagen RNAEasy kit per manufacturer's protocol (Qiagen, Valencia, CA). RNA was quantitated spectrophotometrically and 2 Ag RNA were used to generate cDNA using Thermoscript RT-PCR Reaction System (Invitrogen, Carlsbad, CA) per manufacturer's protocol. PCR reaction was done using the following primers: E2F1, 5V -CATCCAGCTCATTGCCAAGAAG-3V , 5V -GTCCGGTCCTCCCCAGAGGATG-'3'; E2F2, 5V -AAGAAGTTCATT-TACCTCCTGA-3V , 5V -AATCACTGTCTGCTCCTTGAA-3V ; E2F4, 5V -CAAA-GAGCTGTCAGAAATCTTC-3V, 5V-TTGTAGATGTAATCGTGGTCTCC-3V ; E2F5, 5V -GAATTGAAGGAAAGAGAACTTG-3V, 5V-AAACCACTGGCTTAGAT-GAA-3V ; DP-1, 5V -CGCCTCCTCCCAACTCTGTCATC-3V , CAGCATCC-CATCTGCACCATTGCT-3V ; DP-2, 5V -TGCAGCATCTCCAGTGAC-3V , 5V-CAGAGAGCATTTGCCTGAC-3V ; and hypoxanthine phosphoribosyltransferase (HPRT), 5V -CAGTACAGCCCCAAAATGGT-3V , 5V -TTACTAGGCAGATGGC-CACA-3V . PCR was done using a Thermocycler with an annealing temperature of 59jC. HPRT was used as an internal control. Ten-microliter aliquots were removed at cycle number 25, 28, 31, and 34. Reaction products were electrophoresed in a 0.8% agarose gel in 0.5Â TAE buffer (20 mmol/L Tris, 0.5 mmol/L EDTA, adjusted to pH 7.5) for 2 hours at 100 V. DNA products were visualized with ethidium bromide staining under UV light.
Immunofluorescence. Cells grown in four-well chamber slides were washed twice with PBS before fixation in 4% formaldehyde for 5 minutes followed by fixation in 100% ice-cold ethanol for 5 minutes. Fixed cells were washed twice in PBS and then incubated with 0.1% FBS/1% milk/TBST [10 mmol/L Tris (pH 7.6), 250 mmol/L NaCl, 0.25% Tween 20] for 30 minutes to block nonspecific binding. Cells were incubated with antibodies to E2F1 (C-20, Santa Cruz Biotechnology, Santa Cruz, CA), DP-1 (K-20, Santa Cruz Biotechnology), and Rb (PharMingen) in 0.1% FBS/1% milk/TBST for 1 hour at room temperature followed by incubation with Rhodamine-conjugated goat anti-rabbit or goat anti-mouse secondary antibody (Santa Cruz Biotechnology). Nuclear staining was detected using 1 Ag/mL 4V ,6-diamidino-2-phenylindole (DAPI, Molecular Probes, Eugene, OR). Cells were washed with TBST and mounted with Aqua Poly/Mount (Polysciences, Inc., Warrington, PA). To image the signal, conventional fluorescence microscopy was done with a photomicroscope (Olympus, Melville, NY) equipped with an epifluorescence attachment.
Western blot analysis. Whole cell protein lysates were prepared from PrE and RbÀ/ÀPrE cells as previously described (32) . Supernatants were quantitated using a Bradford microtiter assay and denatured with a reducing 2Â sample loading buffer for 5 minutes at 100jC. All proteins were separated on Tris/glycine precast NOVEX gels and analyzed utilizing the ECL detection system (Amersham Biosciences, Piscataway, NJ) as previously described (32) . Primary antibodies were obtained as follows: COX-1 (Cayman Chemical), COX-2 (Cayman Chemical), Rb (14001A, PharMingen), E2F1 (KH-20, PharMingen), p19 ARF (Ab-80, Abcam, Cambridge, United Kingdom), Cyclin A (H-432, Santa Cruz Biotechnology), Cyclin D (A-12, Santa Cruz Biotechnology), Cyclin E (M-20, Santa Cruz Biotechnology), c-myb (C-2, Santa Cruz Biotechnology), and h-actin (Santa Cruz Biotechnology). Appropriate secondary antibodies goat anti-rabbit and goat anti-mouse were obtained from Bio-Rad (Hercules, CA). Signals were detected by enhanced chemiluminescence signal (Bio-Rad) by X-ray film (Kodak, Rochester, NY).
Northern blot analysis. Total RNA was extracted from cells using Qiagen RNA Easy kit per manufacturer's protocol. Northern blot analysis was done using 20 Ag total RNA run on a 4% formaldehyde denaturing agarose gel in 1Â N-morpholinopropanesulfonic acid (MOPS) buffer [0.2 mol/L MOPS, 10 mmol/L EDTA, 10 mmol/L sodium acetate (pH 7.0)] and transferred to a nylon membrane (Stratagene, La Jolla, CA) in 20Â SSC [3 mol/L NaCl, 0.3 mol/L sodium citrate (pH 7.0)] overnight using capillary action. The RNA was cross-linked to the membrane using a Stratagene UV cross-linker and then incubated for 15 minutes at 65jC in hybridization buffer (250 mmol/L Na 2 HPO 4 and 7% SDS). Hybridization was done at 65jC overnight in hybridization buffer containing cDNA probes for COX-2, E2F-1,
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Cancer Res 2005; 65: (9 or h-actin labeled with a-32 P ATP (2 Â 10 6 cpm/mL) using Random Primer Labeling kit (Stratagene) per manufacturer's protocol. The COX-2 cDNA probe was a 581 bp PCR product made using the following primers: sense 5V -ACTCACTCAGTTTGTTGAGTCATTC-3V , antisense 5V -TTTGATTAGTACTG-TAGGGTTAATG-3V . The E2F1 cDNA probe is a 1.1 kb fragment generated from mouse E2F1 cDNA cut with BamHI and Xho1 restriction endonucleases. The h-actin probe is a 900 bp PCR product generated from the following primers: sense 5V -TACAGCTTCACCACCACAGC-3V , antisense 5V -ACAGAAGCAATGCTGTCACC-3V. Following the overnight incubation with the respective 32 P-labeled probes, the membrane was washed twice with 20 mmol/L Na 2 HPO 4 and 5% SDS for 45 minutes each at 65jC, followed by two washes with 20 mmol/L Na 2 HPO 4 and 1% SDS for 45 minutes each at 65jC. The membrane was exposed to film (Kodak) overnight.
Prostaglandin E 2 analysis. Cells (1 Â 10
5
) were plated per well in a sixwell plate. Culture media was collected at 24, 48, 72, and 96 hours. Fifty microliters of centrifuged supernatant from each sample were analyzed for prostaglandin E 2 (PGE 2 ) production using PGE 2 enzyme immunoassay system per manufacturer's protocol (Cayman Chemical). PGE 2 from each supernatant was measured in triplicate using Dynatech Laboratories Microplate Reader (Dynatech Laboratories, Chantilly, VA).
Generation of E2F1-overexpressing cells. PrE cells were trypsinized, plated in 100 mm 2 dishes, and allowed to reach 70% confluence before transfection. Ten micrograms E2F1 cDNA or pCDNA (empty vector control) plasmids containing a neomycin resistance gene were transfected into PrE cells using TFx50 transfection reagent (Promega, Madison, WI) following manufacturer's protocol. Cells were incubated for 72 hours, and then the media was changed to RPMI 1640 containing 5% FBS, 0.1% penicillin/ streptomycin, and 200 Ag G418 (Sigma Chemical, Co., St. Louis, MO). Cells were replenished with fresh media containing 200 Ag G418 every 4 days and selected for stable expressing clones.
Transient transfection and plasmid constructs. PrE and RbÀ/ÀPrE cells were plated at a density of 2 Â 10 5 cells per well in a six-well dish and incubated for 24 hours at 37jC before transfection. Cells were cotransfected with 1 Ag COX2-Luc, dihydrofolate reductase (DHFR)-Luc, or E2F-Luc with or without 0.5 Ag pCDNA (empty vector control), wild-type E2F1, Eco 132, or E2F1 . h-galactosidase (0.1 Ag) was cotransfected for normalization purposes. The COX2-Luc construct was purchased from Oxford Biomedical Research Laboratories (Rochester, MI); E2F1 cDNA construct was kindly provided by Tony Kouzarides (Wellcome/Cancer Research UK Institute, Cambridge, United Kingdom); DHFR-Luc, E2F-Luc, Eco132, and E2F1 were kindly provided by W. Douglas Cress (Moffitt Cancer Center, Tampa, FL); the full-length c-myb and dominant-negative c-myb constructs were kindly provided by Mansoor Husain (University of Toronto, Toronto, Canada); and the h-galactosidase cDNA construct was purchased from Promega. Cells were transfected with the appropriate constructs using Tfx50 transfection reagent (Promega) following the manufacturer's protocol for 72 hours. To prepare whole cell protein lysates, cells were washed once with PBS and cells were harvested by cell scraping. Cells were lysed in Tropix Lysis Buffer (Applied Biosystems, Foster City, CA), freeze thawed, and centrifuged. Supernatants were collected, luciferase activity was monitored using luciferin substrate (Promega), and relative light units were measured using a Monolight 2010 luminometer. To assay hgalactosidase activity, cell lysates were incubated for 1 hour with hgalactosidase substrate (Applied Biosystems) and luminescence was monitored using Monolight 2010 luminometer. Each sample was done in triplicate and the luciferase activity was normalized to h-galactosidase activity to determine results. The results are expressed as the average of three independent experiments with the indicated SD.
Results
Increased COX-2 expression in UGM+RbÀ/À À/À prostate tissues and RbÀ/À À/ÀPrE prostate epithelial cell lines. To identify novel properties that distinguish wild-type prostate epithelial cells from prostate epithelial cells with RB deletion, we compared gene expression profiles of established wild-type PrE and RbÀ/ÀPrE prostate epithelial cell lines using microarray analysis. Among the genes that were differentially expressed, we noted that COX-2 was up-regulated 8-fold in RbÀ/ÀPrE prostate epithelial cells compared with wild-type PrE cells (data available at http:// www.ncbi.nlm.nih.gov/geo/, series number GSE934). This gene was of immediate interest because of multiple studies implicating COX-2 as an important modulator of tumorigenesis (6, 7, 10, 34) . Supporting these findings, we independently observed that COX-2 staining was substantially elevated in UGM+RbÀ/À prostate tissue recombinants. In wild-type UGM+Rb+/+ tissues (Fig. 1A-a and c) , the majority of the glands were lined with single columnar luminal epithelial cells with low COX-2 staining; however, there were some sporadic areas of epithelial hyperplasia, which correlated with increased COX-2 stain intensity. In contrast, UGM+RbÀ/À tissues predominantly exhibited regions of hyperplasia with strong COX-2 staining (Fig. 1A-b and d) . Overall, UGM+RbÀ/À tissue recombinants have increased COX-2 staining in individual cells and an increase in the number of COX-2-positive cells in areas of hyperplasia, suggesting that loss of Rb leads to increased COX-2 expression in prostate epithelial cells.
We next examined COX-2 protein expression in two wild-type PrE and four RbÀ/ÀPrE cell lines derived from UGM+Rb+/+ and UGM+RbÀ/À recombinant tissues. Figure 1B shows increased COX-2 expression in RbÀ/ÀPrE cell lines compared with PrE control cell lines. COX-2 levels were relatively low in PrE cell lines and high in all RbÀ/ÀPrE cell lines. As a control, we show positive Rb protein expression in PrE cells and absence of Rb in RbÀ/ÀPrE cell lines. We also examined COX-1 levels in PrE and RbÀ/ÀPrE cells and observed relatively low levels of COX-1 in RbÀ/ÀPrE cells and slightly elevated levels of COX-1 in PrE cells (Fig. 1B) . Increased COX-2 mRNA was confirmed by Northern blot analysis from total RNA isolated from PrE and RbÀ/ÀPrE cell lines (Fig. 1C) . These results confirm that COX-2 expression is upregulated in RbÀ/ÀPrE cell lines and UGM+RbÀ/À tissues.
To determine differences in basal transcriptional activity of the COX-2 promoter, we assayed expression levels of a promoter construct containing the 5V -flanking sequences corresponding to bp À3,195 to +39 relative to the transcription start site of the mouse COX-2 promoter, cloned in front of a luciferase reporter gene (COX2-Luc). To normalize for transfection efficiency, cells were cotransfected with a cytomegalovirus promoter-driven h-galactosidase reporter gene construct (h-gal). Figure 1D shows that RbÀ/ÀPrE cells have 4-fold increase in basal COX-2 promoter activity compared with PrE cells. As a negative control, cells were also transfected with a promoterless expression vector (Basic-Luc). This result confirms with the microarray analysis and Northern blot analysis and shows that COX-2 is transcriptionally up-regulated in prostate epithelial cells with homozygous deletion of RB. Together, these results suggest that the loss of RB in prostate epithelial cells results in increased COX-2 expression, as shown in vitro and in vivo.
High levels of prostaglandins are produced by RbÀ/À À/ÀPrE cells. The rate-limiting step in the conversion of free arachidonic acid to prostaglandins is catalyzed by COX (reviewed in ref.
2). Given the observation that COX-2 levels are elevated in RbÀ/ÀPrE cells, we wanted to determine if prostaglandin synthesis was elevated RbÀ/ÀPrE prostate epithelial cells in vitro. RbÀ/ÀPrE cells produced 10-fold greater PGE 2 levels compared with PrE cells after 24 hours (2600 pg/mL for RbÀ/À cells versus 226 pg/mL for PrE cells) and continued to have elevated PGE 2 levels over 4 days ( Fig. 2A) . To show that COX-2 is a major contributor to PGE 2 synthesis, we treated cells with increasing concentrations of the specific COX-2 inhibitor, NS-398. As shown in Fig. 2B , NS-398 significantly inhibited PGE 2 synthesis in PrE and RbÀ/ÀPrE cell lines. After 24 hours, the lowest concentration, 10 Amol/L NS-398, decreased PGE 2 levels 90% in PrE cells (316-3.2 pg/mL) and 99% in RbÀ/ÀPrE cells (3,312-2.0 pg/mL). These results show that COX-2 is a major contributor to PGE 2 synthesis in prostate epithelial cells. As a control, we also examined whether COX-1 contributes to PGE 2 synthesis in PrE and RbÀ/ÀPrE cells. Cells were treated with increasing concentrations of the specific COX-1 inhibitor; VSA and supernatants were assayed for PGE 2 synthesis. As shown in Fig. 2B , VSA did not significantly inhibit PGE 2 levels in PrE or RbÀ/ÀPrE cells. This suggests that COX-2 is the major contributor to PGE 2 production in PrE and RbÀ/ÀPrE cells.
RbÀ/À À/ÀPrE cells are sensitive to the cyclooxygenase-2 inhibitor NS-398. Prostaglandins have been shown to increase cell growth of prostate epithelial cells (35) and COX-2 inhibitors have been shown to inhibit cell growth of LNCaP, PC3, and DU-145 prostate cancer cells (36) . We wanted to assess whether NS-398 had the ability to regulate the growth of PrE and RbÀ/ÀPrE cells. Cells were treated with increasing concentrations of NS-398 for 4 days and cell growth was determined. Figure 2C Increased E2F1 activity in RbÀ/À À/ÀPrE cells. We wanted to explore the mechanism by which loss of RB in prostate epithelial cells results in increased COX-2 expression. Studies assessing RB deletion have reported increased E2F activity following loss of RB (37, 38) . Considering that E2F is a major Rb-regulated protein and a transcriptional regulator of many genes, we hypothesized that the loss of RB in prostate epithelial cells leads to increased activation of E2F, which then increases COX-2 transcription. To test this hypothesis, we first assessed expression levels of E2F family members in PrE and RbÀ/ÀPrE cells by semiquantitative reverse transcription-PCR (RT-PCR) analysis, using specific primers to E2F 1 to 5. After confirmation of linear amplification of the PCR products, as shown in Fig. 3A , the gene expression levels were compared. The mRNA levels of the transcriptional activator, E2F1, were slightly increased in RbÀ/ÀPrE cells compared with PrE cells. E2F1 has E2F binding sites in its promoter and is transcriptionally regulated by E2F (39) . Furthermore, increased E2F1 expression has been reported in cells with germ line deletion of RB (40) , which is consistent with our results. Similar gene expression levels were detected for the transcriptional activator E2F2 and the transcriptional repressors, E2F4 and E2F5. We could not detect E2F3 expression in either PrE or RbÀ/ÀPrE cells using multiple primers to E2F3; however, we were able to detect E2F3 in NIH 3T3 positive control cells (data not shown), suggesting that E2F3 levels are below detection by RT-PCR. These results show that E2F1, E2F2, E2F4, and E2F5 are present in PrE and RbÀ/ÀPrE cells and that E2F1 levels are elevated in RbÀ/ÀPrE cells, which is consistent with previous studies describing the effects of RB deletion (40) .
The transcriptional regulatory activity of E2F depends on the ability to heterodimerize to DP-1 and DP-2; therefore, we examined expression levels of DP-1 and DP-2 by semiquantitative RT-PCR over a linear range of amplification. We observed a slight increase in DP-1 mRNA expression RbÀ/ÀPrE cells compared with PrE cells (Fig. 3A) , whereas DP-2 levels were similar between the cell lines. Elevated DP-1 mRNA levels have also been observed in mouse embryonic fibroblasts with RB deletion and in cells with increased E2F activity, indicating that Rb/E2F complex may transcriptionally regulate DP-1 (41, 42) .
Subcellular localization of E2F is critical for its transcriptional activity. E2F1 can be differentially located in cells, but must be in the nucleus to be transcriptionally active. We assessed the subcellular localization of E2F1, the most well-characterized E2F family member, in PrE and RbÀ/ÀPrE cells by immunohistochemistry. We observed differential subcellular localization of E2F1 in PrE cells compared with RbÀ/ÀPrE cells. Figure 3B shows that E2F1 is predominantly cytoplasmic in PrE cells with minimal staining in the nucleus. In contrast, there is greater E2F1 nuclear staining in RbÀ/ÀPrE cells. The subcellular localization of DP-1 and DP-2 were similar in PrE and RbÀ/ÀPrE cells (Fig. 3B) . The increase in E2F1 nuclear localization in RbÀ/ÀPrE cells is suggestive of increased E2F activity; however, to directly assess E2F activation in PrE and RbÀ/ÀPrE cells, we examined protein expression levels of known E2F target genes. E2F target genes known to be activated by E2F1 (Cyclin A, Cyclin D, Cyclin E, and p19 ARF ) were selected for Western blot analysis. Figure 3C shows increased protein expression of Cyclin A, Cyclin D, Cyclin E, and p19 ARF in all four RbÀ/ÀPrE cell lines compared with PrE cells. This is consistent with the model that E2F activity is increased in RbÀ/ÀPrE cells.
To further show specific activation of E2F target promoters in RbÀ/ÀPrE cells, we investigated basal activation of two E2F target promoters, one containing four adjacent E2F consensus binding sites linked to a luciferase reporter gene (E2F-Luc) and a second construct containing the well-characterized E2F target gene promoter, DHFR , linked to a luciferase reporter gene (DHFRLuc). Cells were cotransfected with h-gal to normalize for transfection efficiency. Figure 3D shows that E2F-Luc activity is 4-fold higher in RbÀ/ÀPrE cells compared with PrE cells, and DHFR-Luc activity is 7-fold higher in RbÀ/ÀPrE cells compared with wild-type control. Taken together, increased E2F1 nuclear expression in RbÀ/ÀPrE cells, with elevated levels of E2F target genes (E2F1, Cyclin A, Cyclin D, Cyclin E, and p19 ARF ) and increased activation of E2F specific promoter-luciferase constructs, strongly supports the model of increased E2F activity in RbÀ/ÀPrE cells. Our results are consistent with other reports demonstrating increased E2F target gene expression and E2F activity in cells with loss of RB (37, 38, 40) .
E2F1-overexpressing prostate epithelial cells have increased cyclooxygenase-2 mRNA and protein levels and increased prostaglandin E 2 synthesis. Given the increased transcriptional activity of E2F and increased COX-2 expression levels in RbÀ/ÀPrE cells, we investigated whether E2F1 regulates COX-2 expression in Figure 2 . RbÀ/ÀPrE cells have increased PGE 2 synthesis and are sensitive to the growth inhibitory effects of NS-398. A, increased PGE 2 synthesis in RbÀ/ÀPrE cells. An equal number of PrE and RbÀ/ÀPrE cells were plated and incubated for 4 days. Supernatants were removed at the indicated time and assayed for PGE 2 production by ELISA assay. Each sample was measured in triplicate. Columns, mean of three independent experiments; bars, SD. B, PrE and RbÀ/À cells were treated with 0, 10, 25, 50, and 100 Amol/L NS-398 or VSA for 24 hours. Supernatants were removed at the indicated time and assayed for PGE 2 production by ELISA assay. Each sample was measured in triplicate. Columns, mean of three independent experiments; bars, SD. C, NS-398 inhibits the growth of RbÀ/ÀPrE cells. PrE and RbÀ/ÀPrE cells were treated with either 0, 25, 50, or 100 Amol/L NS-398 for 4 days. Cell growth was determined by trypan blue exclusion assay. Each sample was measured in triplicate. Points, mean; bars, SD.
prostate epithelial cells. We transfected PrE cells with an E2F1 cDNA construct and generated two stable E2F1-overexpressing cell lines, named PrE2F1-1 and PrE2F1-2, as well as a stable expressing empty vector control (PrE-pCDNA). Using Northern blot analysis, we show increased expression of E2F1 mRNA levels in the stable expressing cells compared with the empty vector control (Fig. 4A) . To show that E2F1-overexpressing clones have increased E2F activity, we show increased protein expression of known E2F target genes, Cyclin A, Cyclin D, Cyclin E, and p19 ARF (Fig. 4B) , and increased activation of DHFR-Luc in PrE2F1-1 and PrE2F1-2 cells (Fig. 4C) . Exogenous expression of E2F1 resulted in increased COX-2 mRNA and protein levels increased COX-2 promoter activity and elevated PGE 2 levels (Fig. 4D) . These results show that exogenous expression of E2F1 positively regulates COX-2 expression and activity in prostate epithelial cells.
Transcriptional activation of the cyclooxygenase 2 promoter by E2F1. To determine whether E2F1 transcriptionally regulates COX-2, COX-2 promoter/luciferase constructs were utilized. PrE and RbÀ/ÀPrE cells were cotransfected with COX2-Luc with increasing amounts of wild-type E2F1 expression vector. As shown Figure 3 . Increased E2F1 activity in RbÀ/À cells. A, semiquantitative RT-PCR of E2F family members 1 to 5 and DP family members in PrE and RbÀ/ÀPrE cells. The linear amplified curve of the PCR product of each sample was examined at three-cycle intervals. PCR products were prepared under appropriate conditions and aliquots were taken at the end of the 25th, 28th, 31st, and 34th cycles. B, subcellular localization of E2F1, DP-1, DP-2, and pRb determined by immunofluorescence. PrE and RbÀ/ÀPrE cells were grown on coverslips, fixed in À20jC ethanol, and immunostained with antibodies against E2F1, Rb, DP-1, and DP-2 followed by Rhodamine-conjugated secondary antibody. Nuclei were visualized with DAPI staining and corresponding panels are represented below appropriate immunostained panel. C, Western blot analysis of PrE and RbÀ/À cells for the detection of E2F1 target genes, Cyclin A , Cyclin D , Cyclin E, and p19 ARF .
h-actin is shown as a loading control. D, PrE and RbÀ/À cells were transiently transfected with 1 Ag of either DHFR-Luc or E2F-Luc for 72 hours. Cells were cotransfected with h-gal for normalization purposes. Results are expressed as fold activation. Columns,mean value of three independent experiments; bars, SD.
Cancer Research
Cancer Fig. 5A, 1 Ag E2F1 activated COX-2 promoter activity 7-fold compared with empty vector control (pCDNA3) in PrE cells and 8-fold in RbÀ/ÀPrE cells. As a positive control, we show that E2F1 activates the well-characterized E2F-inducible promoter DHFR-Luc 10-fold (Fig. 5B) . This activation was dependent on an intact E2F1 DNA-binding domain and an intact transactivation domain because the DNA-binding mutant (Eco132) and deletion of the transactivation domain of E2F1 (E2F1 ) were incapable of activating COX-2 reporter activity. As expected, the E2F1 mutants did not activate the DHFR-Luc, which is known to require both the transactivation and DNA-binding domains. These results indicate that both the DNA-binding domain and transactivation domain of E2F1 are required to activate the COX-2 promoter.
Using computational analysis, we examined the COX-2 promoter for potential E2F consensus binding sites (TTTGCGG/CG/CAAA); however, we were unable to identify any strong E2F1 consensus binding sites. The lack of E2F binding sites in the COX-2 promoter suggests that other mechanisms downstream from E2F1 may be regulating COX-2 transcriptional activity; therefore, we examined our microarray analysis, comparing RbÀ/ÀPrE and PrE cells, for potential transcription factors downstream of E2F1. We found that the transcription factor c-myb was up-regulated 4-fold in RbÀ/ÀPrE cells compared with PrE cells (data available at http:// www.ncbi.nlm.nih.gov/geo/, series number GSE934); furthermore, the c-myb transcription factor has been shown to directly activate the COX-2 promoter in human colon cancer cells (43) . We, therefore, investigated whether E2F1-activation of COX-2 is mediated by c-myb.
The c-myb oncogene mediates E2F1-dependent activation of cyclooxygenase-2 promoter. The c-myb oncogene is an E2F1 target gene that is up-regulated in E2F overexpressing cells (44) . We confirmed that c-myb protein expression was elevated in Figure 4 . Overexpression of E2F1 increases COX-2 levels in prostate epithelial cells. A, Northern blot analysis of stably transfected PrE-pCDNA (empty vector control) and two E2F1-overexpressing cell lines, PrE2F1-1 and PrE2F1-2. Membranes were incubated with probes for either E2F1 or COX-2. h-actin is shown as a loading control. B, Western blot analysis to detect COX-2 and E2F target genes Cyclin A , Cyclin D , Cyclin E , and p19 ARF in stably transfected PrE-pcDNA, PrE2F1-1, and PrE2F1-2 cells. C, control and E2F1-overexpessing cells were transiently transfected with 1 Ag of either Basic-Luc, COX2-Luc, or DHFR-Luc for 72 hours. Cells were cotransfected with h-gal for normalization purposes. Results are expressed as fold activation. Columns, mean value of three independent experiments; bars, SD. D, PrE-E2F1 overexpressing cells have increased PGE 2 synthesis. Supernatants from cells stably transfected with either pCDNA (empty vector) or E2F1 were analyzed for PGE 2 production using an ELISA assay. Each sample was measured in triplicate. Points, mean; bars, SD. RbÀ/ÀPrE cells and PrE2F1-overexpressing cells by Western blot analysis. Figure 6A shows increased c-myb protein expression in RbÀ/ÀPrE cells compared with PrE cells and increased c-myb expression in prostate epithelial cells stably transfected with E2F1. To further characterize a mechanism responsible for increased COX-2 expression in RbÀ/ÀPrE and E2F1 overexpressing cells, we investigated whether E2F1 activation of COX-2 is mediated by c-myb. To test this, we first assessed whether c-myb could activate the COX-2 promoter in prostate epithelial cells. PrE cells were cotransfected with COX2-Luc and a full-length c-myb cDNA construct. Figure 6B shows that c-myb activates COX2-Luc 7-fold, similar to results reported in human colon cancer cells by Ramsay et al. (43) . Cotransfection with a dominant-negative c-myb construct, which lacks the DNAbinding domain (DN c-myb), completely inhibited activation of COX2-Luc by c-myb (Fig. 6B) . As shown in Fig. 6C , cotransfection of dominant-negative c-myb with E2F1 completely abrogated E2F1 activation of COX2-Luc, indicating that activation of the COX-2 promoter by E2F1 is dependent on the activity of c-myb.
Discussion
There is strong evidence to implicate COX-2 in human colon cancer, breast cancer, and lung cancer; however, a common consensus for COX-2 in prostate tumorigenesis has not been established (3) (4) (5) (6) . Some reports document elevated COX-2 levels in prostate cancer tissue and HGPIN lesions as well as areas of proliferative inflammatory atrophy, a precursor to prostate cancer (10) (11) (12) 17) . In contrast, other studies have shown increased COX-2 expression in normal prostate tissue and minimal COX-2 expression in prostate cancer and prostate cancer cell lines (13, 14) . Animal models of prostate cancer have shown increased COX-2 expression in hyperplasia, in prostate cancer, and in metastatic lesions (16, 17) . Overexpression of COX-2 in LNCaP cells promotes tumors in severe combined immunodeficient mice and inhibition of COX-2 can prevent tumor formation in metastasis in animal models (7) . In our study, we observed increased COX-2 expression in UGM+RbÀ/À prostate recombinant tissue grafts, which was confirmed in RbÀ/ÀPrE prostate epithelial cell lines. Increased COX-2 expression correlated with areas of hyperplasia in vivo. Interestingly, the UGM+RbÀ/À tissues are susceptible to hormonal carcinogenesis in vivo (33), suggesting a role of COX-2 in precursor or early prostatic lesions.
Elevated COX-2 expression has been observed in two transgenic mouse models of prostate cancer with nonfunctional Rb (16, 17) . In both studies, the probasin promoter was used to target SV40 large T antigen to the luminal prostatic epithelial cells. SV40 large T disrupts both p53 and Rb to promote tumorigenesis. COX-2 expression was high in HGPIN lesions as well as early stages of prostate cancer, but absent in late-stage tumors and in metastasis (16, 17) . Furthermore, the COX-2 inhibitor Celecoxib inhibited prostate tumor progression and reduced metastasis in the TRAMP model. Although the use of viral oncogenes, such as large T antigen, are useful to promote oncogenesis, they also target additional cellular molecules, thereby limiting the ability to study a specific molecular mechanism and making interpretation of experimental results difficult. In our study, we specifically disrupted RB while maintaining wild-type p53 in the RbÀ/À cells (32) and show that either loss of RB or exogenous overexpression of E2F1 results in increased COX-2 expression with increased prostaglandin synthesis. The increase in COX-2 was associated with areas of hyperplasia in vivo and increased E2F1 activity in vitro, supporting the role that disruption of Rb or activation of E2F1 is important in COX-2 regulation and may be important in early prostate tumorigenesis. In our study, we report that the COX-2 inhibitor NS-398 was selective in inhibiting RbÀ/ÀPrE cell growth and did not inhibit growth of normal prostate epithelial cells. Because the RbÀ/À prostate recombinant tissues develop prostate cancer following testosterone and estrogen treatment, it would be interesting to determine if COX-2 inhibitors could prevent hormonal carcinogenesis in RbÀ/À prostate tissues.
The exact function of COX-2 in promoting tumor development is not known; however, there are several molecular mechanisms Figure 6 . Effect of dominant-negative c-myb on E2F1-induced COX-2 promoter activation. A, the oncogene c-myb is up-regulated in RbÀ/ÀPrE and E2F1-overexpressing cells. Whole cell lysates from PrE, RbÀ/ÀPrE, PrE-pCDNA (empty vector control), PrE2F1-1, and PrE2F1-2 cells were subjected to Western blot analysis for the detection of c-myb . h-actin is shown as a loading control. B, oncogenic c-myb activates COX-2 promoter activity in prostate epithelial cells. PrE cells were transiently transfected with COX2-Luc and either pCDNA (empty vector), E2F1, c-myb , or dominant-negative c-myb (DN c-myb ). Forty-eight hours after transfection, cells were lysed and assayed for luciferase and h-gal. Each experiment was done in triplicate. Columns, mean; bars, SD. C, dominant-negative c-myb abrogates E2F1-induced COX-2 promoter activation. PrE cells were cotransfected with COX2-Luc and a combination of pCDNA, E2F1, c-myb and DN c-myb . Forty-eight hours after transfection, cells were lysed and assayed for luciferase and h-gal. Each experiment was done in triplicate. Columns, mean; bars, SD.
described for COX-2 in promoting cell growth. COX-2 induces prostaglandin synthesis and prostaglandins have growth-promoting effects in prostate cancer cells (35) . PGE 2 stimulated primary prostate cancer cell growth through activation of interleukin-6 and signal transducers and activators of transcription 3 signaling molecules (36) . The COX-2 inhibitor Celecoxib can inhibit Akt activation and induce apoptosis in human cancer cells (45) . It remains to be determined if NS-398 induced apoptosis in RbÀ/ÀPrE cells. Other mechanisms have been described for COX-2, including the production of reactive oxygen radicals during the conversion of arachidonic acid to prostaglandin, which may contribute to DNA oxidative damage and induction of genetic mutations (46) . COX-2 may play a role in angiogenesis by up-regulating vascular endothelial growth factor (VEGF) levels (47) . Interestingly, we detected increased VEGF mRNA levels in RbÀ/ÀPrE cells by microarray analysis http://www.ncbi.nlm.nih.gov/geo/, series number GSE934), suggesting another consequence of Rb/E2F deregulation is upregulation of VEGF.
Deregulation of E2F1 through impairment of Rb occurs in tumors. This deregulation can occur through mutation of the RB gene, overexpression of Cyclin D, or inactivation of 16 INK4A cyclindependent kinase (23) . The growth inhibitory protein p16
INK4A
inhibits Cyclin D-dependent kinases, which, in turn, phosphorylate Rb. In a recent study by Crawford et al. (48) , silencing of p16 INK4A gene expression through promoter hypermethylation resulted in increased COX-2 levels and elevated PGE 2 synthesis in mammary epithelial cells. The increased COX-2 expression contributed to increased angiogenic activity and invasiveness; furthermore, the COX-2 inhibitor NS-398 was able to reduce cell survival and increase apoptosis in mammary epithelial cells. These studies support our findings that disruption of the Rb pathway plays a regulatory role in COX-2.
Previous reports have documented that loss of RB results in increased expression of E2F target genes and increased E2F activity (37, 38, 49) . We have observed increased expression of E2F target genes, Cyclin A, Cyclin D, Cyclin E, p19 ARF , E2F1, and c-myb, as well as increased activation of E2F-specific promoter/luciferase constructs in the RbÀ/ÀPrE cells, supporting the model of increased activation of E2F in RbÀ/ÀPrE cells. We argue that the increase in COX-2 expression observed in RbÀ/ÀPrE cells is mediated in part by E2F. This hypothesis is supported by the fact that exogenous E2F1 transcriptionally activated COX-2 expression in prostate epithelial cells, which required both E2F1 DNA-binding and transactivation domains. We have also shown that c-myb, an E2F1 target gene (44, 50) , is up-regulated in RbÀ/ÀPrE cells and E2F1-overexpressing cells and exogenous expression of c-myb activated the COX-2 promoter in mouse prostate epithelial cells. These results agree with the study by Ramsay et al. (43) , who identified c-myb binding sites in the COX-2 promoter and showed transcriptional regulation of the COX-2 promoter by c-myb in human colon cancer cells. We show that a dominant-negative c-myb construct, which lacks the DNA-binding domain, abrogates E2F1-mediated activation of the COX-2 promoter. We suggest that c-myb mediates E2F1-directed transcription of COX-2. Because c-myb is an oncogenic transcription factor and is overexpressed in human leukemias (51) , lung cancer (52) , and colon cancer (53), the expression and activity of c-myb should be examined in prostate tumorigenesis.
In summary, we have in vitro and in vivo evidence to show that deletion of Rb and increased expression of E2F1 result in increased COX-2 expression and function in prostate epithelial cells. COX-2 expression correlates with increased PGE 2 synthesis. Our data indicate that NS-398 can directly target epithelial cells with loss of Rb and increased COX-2 expression, thereby supporting the role for COX-2 inhibitors in prostate chemoprevention. Finally, the identification of E2F1 as a transcriptional regulator of COX-2 implicates that E2F1 has multiple targets in addition to cell cycle regulatory proteins that can contribute to cancer development and progression, possibly through upregulation of the oncogene, c-myb.
